Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Tumor-homing effect of human mesenchymal stem cells in a TH-MYCN mouse model of neuroblastoma.

Kimura K, Kishida T, Wakao J, Tanaka T, Higashi M, Fumino S, Aoi S, Furukawa T, Mazda O, Tajiri T.

J Pediatr Surg. 2016 Dec;51(12):2068-2073. doi: 10.1016/j.jpedsurg.2016.09.041. Epub 2016 Sep 17.

PMID:
27686479
2.

Novel Mesenchymal Stem Cell Delivery System as Targeted Therapy Against Neuroblastoma Using the TH-MYCN Mouse Model.

Maniwa J, Fumino S, Kimura K, Tanaka T, Higashi M, Kishida T, Mazda O, Tajiri T.

J Pediatr Surg. 2019 Aug 30. pii: S0022-3468(19)30563-9. doi: 10.1016/j.jpedsurg.2019.08.023. [Epub ahead of print]

PMID:
31627888
3.

Combination of single-photon emission computed tomography and magnetic resonance imaging to track 111in-oxine-labeled human mesenchymal stem cells in neuroblastoma-bearing mice.

Cussó L, Mirones I, Peña-Zalbidea S, García-Vázquez V, García-Castro J, Desco M.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00033.

PMID:
25248941
4.

Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition.

Bianchi G, Morandi F, Cilli M, Daga A, Bocelli-Tyndall C, Gambini C, Pistoia V, Raffaghello L.

PLoS One. 2012;7(10):e48654. doi: 10.1371/journal.pone.0048654. Epub 2012 Oct 31.

5.

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.

Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL.

PLoS One. 2011;6(12):e28356. doi: 10.1371/journal.pone.0028356. Epub 2011 Dec 2.

6.

Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts.

Pacioni S, D'Alessandris QG, Giannetti S, Morgante L, Coccè V, Bonomi A, Buccarelli M, Pascucci L, Alessandri G, Pessina A, Ricci-Vitiani L, Falchetti ML, Pallini R.

Stem Cell Res Ther. 2017 Mar 9;8(1):53. doi: 10.1186/s13287-017-0516-3.

7.

Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.

Rasmuson A, Segerström L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P.

PLoS One. 2012;7(12):e51297. doi: 10.1371/journal.pone.0051297. Epub 2012 Dec 17.

8.

Effect of bone-marrow-derived mesenchymal stem cells on high-potential hepatocellular carcinoma in mouse models: an intervention study.

Li T, Song B, Du X, Wei Z, Huo T.

Eur J Med Res. 2013 Sep 30;18:34. doi: 10.1186/2047-783X-18-34.

9.

Administrations of human adult ischemia-tolerant mesenchymal stem cells and factors reduce amyloid beta pathology in a mouse model of Alzheimer's disease.

Harach T, Jammes F, Muller C, Duthilleul N, Cheatham V, Zufferey V, Cheatham D, Lukasheva YA, Lasser T, Bolmont T.

Neurobiol Aging. 2017 Mar;51:83-96. doi: 10.1016/j.neurobiolaging.2016.11.009. Epub 2016 Nov 24.

PMID:
28056358
10.

Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease.

Bossolasco P, Cova L, Levandis G, Diana V, Cerri S, Lambertenghi Deliliers G, Polli E, Silani V, Blandini F, Armentero MT.

Int J Nanomedicine. 2012;7:435-47. doi: 10.2147/IJN.S27537. Epub 2012 Jan 31.

11.

[Influence of human bone marrow-derived mesenchymal stem cells on the lung of newborn rats damaged by hyperoxia].

Tian ZF, Du J, Fu XM, Wang B, Hong XY, Feng ZC.

Zhonghua Er Ke Za Zhi. 2008 Jan;46(1):4-8. Chinese.

PMID:
18353229
12.

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.

Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.

Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.

13.

Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.

Garcia MG, Bayo J, Bolontrade MF, Sganga L, Malvicini M, Alaniz L, Aquino JB, Fiore E, Rizzo MM, Rodriguez A, Lorenti A, Andriani O, Podhajcer O, Mazzolini G.

Mol Pharm. 2011 Oct 3;8(5):1538-48. doi: 10.1021/mp200137c. Epub 2011 Aug 19.

PMID:
21770423
14.

Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth.

Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW, Hui KM.

J Hepatol. 2013 Nov;59(5):999-1006. doi: 10.1016/j.jhep.2013.07.010. Epub 2013 Jul 16.

15.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP.

Radiology. 2013 Jan;266(1):130-40. doi: 10.1148/radiol.12120128. Epub 2012 Nov 20.

16.

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.

Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF.

Cancer Res. 2005 Apr 15;65(8):3307-18. Erratum in: Cancer Res. 2006 Jun 1;66(11):5975.

17.

Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models.

Liu LN, Wang G, Hendricks K, Lee K, Bohnlein E, Junker U, Mosca JD.

Stem Cells Transl Med. 2013 May;2(5):362-75. doi: 10.5966/sctm.2012-0135. Epub 2013 Apr 16.

18.

Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression.

Kawakubo N, Harada Y, Ishii M, Souzaki R, Kinoshita Y, Tajiri T, Taguchi T, Yonemitsu Y.

Biochem Biophys Res Commun. 2018 Sep 10;503(3):1666-1673. doi: 10.1016/j.bbrc.2018.07.097. Epub 2018 Jul 24.

19.

Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.

Quarta C, Cantelli E, Nanni C, Ambrosini V, D'ambrosio D, Di Leo K, Angelucci S, Zagni F, Lodi F, Marengo M, Weiss WA, Pession A, Tonelli R, Fanti S.

Mol Imaging Biol. 2013 Apr;15(2):194-202. doi: 10.1007/s11307-012-0576-9.

20.

Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease.

Park HJ, Lee PH, Bang OY, Lee G, Ahn YH.

J Neurochem. 2008 Oct;107(1):141-51. doi: 10.1111/j.1471-4159.2008.05589.x. Epub 2008 Jul 28.

Supplemental Content

Support Center